UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000030908
Receipt No. R000035292
Scientific Title Influence on ingestion of human ceramide-containing supplement on skin quality/sleep.
Date of disclosure of the study information 2018/11/18
Last modified on 2018/08/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Influence on ingestion of human
ceramide-containing supplement on
skin quality/sleep.
Acronym ceramide human test.
Scientific Title Influence on ingestion of human
ceramide-containing supplement on
skin quality/sleep.
Scientific Title:Acronym ceramide human test.
Region
Japan

Condition
Condition Healthy adults
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To verify the improvement of skin quality and sleep of Japanese adult females by ingestion of human ceramide-containing supplements.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes Skin quality measurement
Sleep scale(PSQI:Pittsburgh Sleep Quality Index)
Key secondary outcomes Physiological examination
Blood biochemical examination
Mood scale (POMS:Profile of Mood Sate)

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification YES
Dynamic allocation NO
Institution consideration Institution is not considered as adjustment factor.
Blocking YES
Concealment No need to know

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 ceramide supplements
1capsule/day
28days
Interventions/Control_2 Placebo supplements
1capsule/day
28days
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
30 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria (1)Female
(2)Age 30 to 70 years old
(3)persons who is generally judged as healthy
(4)Persons who can give voluntary written cons
ent to participate in the present trial
Key exclusion criteria (1)persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study
(2)persons who have changed their habitats to take supplements within past 4 weeks.
(3)Persons who work in night shift or in day and night shift
(4)persons who have been treated their illness or prevention in a clinic at their informed consent
(5)persons with their medical histories as follows: serious diseases of sugar metabolism,lipid metabolism, hepatic function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system
(6)persons with the medical histories of alcoholism or drug dependence
(7)persons who might be developed allergic reaction to foods.
(8)Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period
(9)persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device)
persons who will not be judged suitable to the participants by the investigator.
Target sample size 45

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Koichirou Ohnuki
Organization Faculty of Humanity-Oriented Science and Engineering, Kindai University
Division name Food function science laboratory
Zip code
Address 11-6 Kayanomori, Iiduka, Fukuoka, Japan
TEL 0948-22-5655
Email ohnuki@fuk.kindai.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Keiko Ohnuki Takumi Oohira
Organization User Life Science Co.Ltd
Division name The research and development part
Zip code
Address 372-1 Niho, Izuka, Fukuoka, JAPAN
TEL 0948-82-3123
Homepage URL
Email userlifesciense@gmail.com

Sponsor
Institute User Life Science Co.Ltd
Institute
Department

Funding Source
Organization Fukuoka soy sauce brewing
cooperative
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Faculty of Humanity-Oriented Science and Engineering, Kindai University
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 11 Month 18 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 11 Month 18 Day
Date of IRB
Anticipated trial start date
2017 Year 11 Month 18 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 01 Month 20 Day
Last modified on
2018 Year 08 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035292

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.